This article is more than 5 years old. Information may no longer be current.
Ramucirumab plus FOLFIRI improved OS in metastatic colorectal cancer
Click Here to Manage Email Alerts
Ramucirumab plus FOLFIRI in combination with chemotherapy improved overall survival in metastatic colorectal cancer patients after progression on a bevacizumab-based regimen, according to phase 3 trial results reported recently by Eli Lilly.
“Patients with metastatic colorectal cancer — particularly those in the second-line setting — continue to need new treatment options that improve survival,” Richard Gaynor, MD, senior vice president, product development and medical affairs for Lilly Oncology, said in a press release. “We are pleased that the RAISE study demonstrated a survival benefit and are hopeful that ramucirumab will become a new antiangiogenic treatment option after first-line bevacizumab-containing therapy for metastatic colorectal cancer patients.”
Richard Gaynor
The RAISE trial, a global, randomized, double blind study initiated in 2010 compared ramucirumab (Cyramza) plus FOLFIRI (irinotecan, folinic acid and 5-fluorouracil) with placebo plus FOLFIRI as second-line therapy in more than 1,000 patients who had received treatment with bevacizumab, oxaliplatin and fluoropyrimidine. The ramucirumab group had significantly improved overall and progression-free survival compared with controls, while increased incidence of neutropenia, fatigue, hypertension and diarrhea was observed, the release said.
“We now have four phase 3 ramucirumab trials that improved survival in three of the world’s most common and deadly cancers — gastric, lung and colorectal — supporting global regulatory submissions in multiple indications,” Gaynor said. “The RAISE data also build on Lilly’s growing presence in gastrointestinal cancer therapy.”
The company plans to present this data and initiate regulatory submissions in 2015.